Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To Determine if topical cyclosporine 0.05% BID prevents recurrent inflammation and improves comfort in eyes with pterygia.

• Phase: Phase 4

Details

• Lead Sponsor: Innovative Medical
• Treatments: Cyclosporine; Cyclosporins

Criteria

Inclusion Criteria:

• pts with symptomatic pterygia unresponsive to palliative treatment.